NEW YORK (GenomeWeb News) – Antibody firm Epitomics today announced it has signed a contract with SAIC-Frederick to develop rabbit monoclonal antibodies in support of the National Cancer Institute's proteomics initiative.
SAIC-Frederick operates under a contract with NCI's Clinical Proteomic Technologies for Cancer program.
Under the terms of Epitomics' contract, the Burlingame, Calif.-based company will develop high affinity and renewable reagents to capture tryptic peptides derived from human plasma protein biomarkers. The peptides will then be used to quantify biomarkers by mass spectrometry-based technologies, such as stable isotope standards and capture by anti-peptide antibodies (SISCAPA) and immuno-matrix-assisted laser desorption/ionization (iMALDI), Epitomics said in a statement.
The firm has completed the first phase of the project to generate and affinity-purify rabbit polyclonal antibodies against the biomarkers. It will now move into the second phase to develop rabbit monoclonal antibodies against selected biomarkers that have been validated.
CPTC is a five-year, $104 million effort to develop new proteomics tools and technologies to accelerate discovery and clinical research. One part of the initiative is to develop better antibodies and reagents for the proteomics community.